While Cogent Biosciences Inc has overperformed by 0.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, COGT rose by 55.00%, with highs and lows ranging from $12.97 to $3.72, whereas the simple moving average jumped by 50.72% in the last 200 days.
On March 07, 2025, Scotiabank started tracking Cogent Biosciences Inc (NASDAQ: COGT) recommending Sector Outperform. A report published by Needham on December 11, 2024, Downgraded its rating to ‘Hold’ for COGT. Robert W. Baird also Downgraded COGT shares as ‘Neutral’, setting a target price of $8 on the company’s shares in a report dated February 26, 2024. Citigroup Initiated an Buy rating on February 08, 2024, and assigned a price target of $11. Wedbush December 11, 2023d its ‘Outperform’ rating to ‘Neutral’ for COGT, as published in its report on December 11, 2023. JP Morgan’s report from December 08, 2023 suggests a price prediction of $18 for COGT shares, giving the stock a ‘Overweight’ rating. Robert W. Baird also rated the stock as ‘Outperform’.
Analysis of Cogent Biosciences Inc (COGT)
One of the most important indicators of Cogent Biosciences Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -84.04% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.13, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and COGT is recording 2.82M average volume. On a monthly basis, the volatility of the stock is set at 6.89%, whereas on a weekly basis, it is put at 4.07%, with a loss of -1.71% over the past seven days. Furthermore, long-term investors anticipate a median target price of $19.64, showing growth from the present price of $12.09, which can serve as yet another indication of whether COGT is worth investing in or should be passed over.
How Do You Analyze Cogent Biosciences Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 23.05%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 71.12% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
